{
Novartis AG

Companies

}
Swiss stock market declines as UBS and Sandoz report mixed results
The Swiss stock market experienced a downturn, with the SMI dropping 0.50% amid significant company reports, particularly focusing on UBS and Sandoz. UBS saw profit-taking after reaching a multi-year high, while Sandoz rose 2.7% following strong earnings. Tensions are rising ahead of the US labor market report and the upcoming presidential election, influencing investor behavior.
MarketScreener
Swiss Franc Novartis AG UBS AG Microsoft Corporation Aqua Metals, Inc. Sandoz Group AG CHE Show more
TradFi, Market Report
11:31 30.10.2024
ubs shares reach highest level since 2008 amid strong quarterly results
Ford reported a staggering $1.2 billion operating loss in its electric vehicle division for Q3, contributing to a share price drop of over 5%. Meanwhile, UBS shares surged to their highest level since 2008 after posting a $1.43 billion profit, exceeding expectations. In the tech sector, Alphabet's quarterly profit rose by a third, boosting its share price by 4% in after-hours trading.
Blick
United States Dollar Volkswagen AG Novartis AG UBS AG Alphabet Inc. Ford Motor Company DEU USA Isabel Fritzl Donald Trump Michael Buholzer Show more
TradFi, Market Report
09:25 30.10.2024
Swiss equities rise as UBS reports strong earnings amid busy reporting season
The Swiss stock exchange is experiencing a busy reporting season, with UBS reporting a better-than-expected billion-euro profit and Sandoz raising its sales outlook. The SMI is up 0.27% in pre-market trading, while Novartis received FDA approval for a leukemia treatment. Meanwhile, Swatch faces a "Sell" rating, and Kühne+Nagel sees a decline after a target cut.
MarketScreener
United States Dollar Landis+Gyr Group AG Novartis AG UBS AG Aqua Metals, Inc. Richemont DNS Inc. Booking Holdings Inc. Sandoz Group AG Microsoft Corporation Swatch AG Starbucks Corporation Kühne + Nagel Ltd. eBay Inc. Georg Fischer AG DEU CHE USA Show more
TradFi, Market Report
08:46 30.10.2024
Swiss equities rise as UBS reports strong earnings amid busy reporting season
The Swiss stock exchange is active with the reporting season, highlighted by UBS exceeding profit expectations and Sandoz raising its sales outlook. The SMI is up 0.27%, while major US tech firms, including Microsoft and Meta, are set to report, amid anticipation for the US labor market data. Novartis received FDA approval for a leukemia treatment, while Swatch and Richemont received mixed ratings from Berenberg.
finanzen.ch
Euro United States Dollar Landis+Gyr Group AG Novartis AG UBS AG Aqua Metals, Inc. Richemont DNS Inc. Booking Holdings Inc. Sandoz Group AG Microsoft Corporation Swatch AG Starbucks Corporation Kühne + Nagel Ltd. eBay Inc. Georg Fischer AG DEU CHE USA Show more
TradFi, Market Report
08:45 30.10.2024
Novartis maintains buy rating despite concerns over prostate cancer drug performance
UBS has maintained its "Buy" rating for Novartis, setting a target price of 111 francs, despite a recent disappointment regarding the prostate cancer drug Pluvicto. Analyst Matthew Weston noted that Novartis exceeded expectations overall, but the focus remains on the drug's performance. Currently, Novartis shares are trading at 102.40 EUR, down 3.87%.
finanzen.net
Swiss Franc Euro Novartis AG UBS AG CHE Matthew Weston
TradFi, Market Report
08:02 30.10.2024
biogen reshuffles leadership novartis writes down morphosys assets
Biogen has appointed Daniel Quirk as its new chief medical officer and Robin Kramer as chief financial officer, succeeding Michael McDonnell, who will retire in February. Meanwhile, Novartis has written down $800 million in goodwill related to its MorphoSys acquisition, delaying the approval of the drug pelabresib for myelofibrosis. Additionally, Sanofi has invested in Resalis Therapeutics, which is developing an RNA medicine for metabolic diseases, while Moderna and Merck & Co. have launched a third Phase 3 trial for their personalized cancer vaccine in lung cancer.
BioPharma Dive
United States Dollar Merck & Co., Inc. Resalis Therapeutics Novartis AG Biogen Inc. Moderna, Inc. ITA USA Daniel Quirk Michael McDonnell Robin Kramer Show more
Healthcare, News Article
14:54 29.10.2024
UBS maintains buy rating for Novartis with target price of 111 francs
UBS has maintained a "Buy" rating for Novartis, setting a target price of 111 Swiss francs. Analyst Matthew Weston noted a small sales surprise and a core EPS that exceeded consensus by 6% in his initial assessment of the company's recent figures. Novartis shares are currently trading at 102.40 EUR, down 3.87%.
finanzen.net
Swiss Franc Euro Novartis AG UBS AG CHE Matthew Weston
TradFi, Market Report
11:33 29.10.2024
ubs maintains buy rating for novartis with price target of 111 francs
UBS AG has maintained a "Buy" rating for Novartis shares, setting a price target of 111 francs. Analyst Matthew Weston noted a small sales surprise and a 6% above-consensus result in core EPS. Despite a 3.2% drop to CHF 96.62, the stock has potential for a 14.88% increase, with a year-to-date rise of 18.1%. Novartis is set to release its Q3 2024 earnings on October 29, 2024.
finanzen.ch
Swiss Franc Novartis AG UBS AG CHE Matthew Weston
TradFi, Market Report
11:28 29.10.2024
Novartis AG's global sales and production footprint in pharmaceuticals
Novartis AG, a leading global pharmaceutical company, generates sales primarily from oncology (29.9%), immunology (17.2%), and cardiovascular, renal, and metabolic diseases (14.1%). With 33 production sites worldwide, its sales are distributed across Europe (33%), the USA (39.5%), Asia-Africa-Australasia (20.5%), and Canada and Latin America (7%).
Zonebourse
United States Dollar Novartis AG CHE Show more
TradFi, Market Report
11:25 29.10.2024
Novartis AG's global sales and production strategy in pharmaceuticals
Novartis AG, a leading global pharmaceutical company, generates sales primarily from oncology (29.9%), immunology (17.2%), and cardiovascular, renal, and metabolic diseases (14.1%). With 33 production sites worldwide, its sales are distributed across Europe (33%), the USA (39.5%), Asia-Africa-Australasia (20.5%), and Canada and Latin America (7%).
zonebourse.com
United States Dollar Novartis AG CHE Show more
TradFi, Market Report
11:25 29.10.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Central Bank Actions Market Sentiment Analysis Corporate Responsibility & ESG Banking Regulations Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Tokenomics and Crypto Economics Inflation Rates & CPI Data Cryptocurrency Regulations Market Analysis and Predictions Anti-Money Laundering (AML) Regulations Mergers & Acquisitions SEC & Financial Compliance Hedge Funds & Private Equity Blockchain Technology Adoption Cryptocurrency Developments ESG & Sustainable Finance Regulations
Countries:
USA CHE JPN CHN AUS IND HKG SGP DEU KOR CAN RUS AUT GBR BRA SAU TWN FRA LIE BHR
Companies:
Ripples USD Credit Suisse Real Estate Fund Siat BlackRock, Inc. Solana USD Coinbase Global, Inc. MicroStrategy Incorporated Ethereum USD Tesla, Inc. Apple Inc. NVIDIA Corporation Cardano USD Google Inc. Bitwise Bitcoin ETF Chainlink USD Amazon.com, Inc. Kraken Energy Corp. Sumitomo Corp Oracle Corp Crypto.com Staked ETH USD Palantir Technologies Inc.
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Chinese Yuan Canadian Dollar Colombian Peso Singapore Dollar Indian Rupee Hong Kong Dollar South Korean Won
People:
Donald Trump Ali Martinez Elon Musk Michael J. Saylor Jerome Powell Paul Atkins Gary Gensler David O. Sacks Charles Hoskinson Wiley Nickel Sriram Krishnan Bo Hines Karin Keller-Sutter Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong Aaron Green Joe Biden

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.